Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials.

Wang Z, Shi L, Xu S, Zhang J

Drug design, development and therapy19 Apr 2017Cited by 14 (Europe PMC)

PMID28458521PMCIDPMC5402893DOI10.2147/dddt.s124273PepBankPUB-28458521

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with acute ischemic stroke, Cerebrolysin did not significantly improve modified Rankin Scale response at Day 90 versus placebo.
In plain wordsIn stroke patients, Cerebrolysin did not significantly improve disability response at Day 90 compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeModified Rankin Scale response at Day 90
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Relative risk
1.33
Modified Rankin Scale response at Day 90, Cerebrolysin versus placebo
95% confidence interval for relative risk
0.79 to 2.24
Modified Rankin Scale response at Day 90, Cerebrolysin versus placebo
P value for relative risk comparison
0.28
Modified Rankin Scale response at Day 90, Cerebrolysin versus placebo
Source sentences
Summary
Cerebrolysin had no significant effect on functional recovery at Day 90 compared with the effect of placebo as shown by the modified Rankin Scale response (relative risk [RR] 1.33, 95% confidence interval [CI] 0.79-2.24, P=0.28)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 1,649 patients with AIS were pooled from six randomized controlled trials (RCTs).
Report a problemFND-2845852101
02HumanSystematic reviewEfficacy outcome
In patients with acute ischemic stroke, Cerebrolysin did not significantly improve NIH Stroke Scale response at Day 90 versus placebo.
In plain wordsIn stroke patients, Cerebrolysin did not significantly improve neurological response at Day 90 compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeNIH Stroke Scale response at Day 90
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Relative risk
1.03
NIH Stroke Scale response at Day 90, Cerebrolysin versus placebo
95% confidence interval for relative risk
0.83 to 1.28
NIH Stroke Scale response at Day 90, Cerebrolysin versus placebo
P value for relative risk comparison
0.77
NIH Stroke Scale response at Day 90, Cerebrolysin versus placebo
Source sentences
Summary
National Institutes of Health Stroke Scale response (RR 1.03, 95% CI 0.83-1.28, P=0.77)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 1,649 patients with AIS were pooled from six randomized controlled trials (RCTs).
Report a problemFND-2845852102
03HumanSystematic reviewEfficacy outcome
In patients with acute ischemic stroke, Cerebrolysin did not significantly improve Barthel Index response at Day 90 versus placebo.
In plain wordsIn stroke patients, Cerebrolysin did not significantly improve daily-function response at Day 90 compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeBarthel Index response at Day 90
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Relative risk
0.95
Barthel Index response at Day 90, Cerebrolysin versus placebo
95% confidence interval for relative risk
0.84 to 1.08
Barthel Index response at Day 90, Cerebrolysin versus placebo
P value for relative risk comparison
0.44
Barthel Index response at Day 90, Cerebrolysin versus placebo
Source sentences
Summary
Barthel Index response (RR 0.95, 95% CI 0.84-1.08, P=0.44).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 1,649 patients with AIS were pooled from six randomized controlled trials (RCTs).
Report a problemFND-2845852103
04HumanSystematic reviewSafety outcome
In patients with acute ischemic stroke, Cerebrolysin did not significantly increase adverse-event risk versus placebo.
In plain wordsIn stroke patients, Cerebrolysin did not significantly increase side-effect risk compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeAdverse events
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Relative risk
0.98
Adverse events, Cerebrolysin versus placebo
95% confidence interval for relative risk
0.88 to 1.09
Adverse events, Cerebrolysin versus placebo
P value for relative risk comparison
0.67
Adverse events, Cerebrolysin versus placebo
Source sentences
Summary
In safety analysis, cerebrolysin did not increase the risk of adverse events (RR 0.98, 95% CI 0.88-1.09, P=0.67)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 1,649 patients with AIS were pooled from six randomized controlled trials (RCTs).
Report a problemFND-2845852104
05HumanSystematic reviewSafety outcome
In patients with acute ischemic stroke, Cerebrolysin did not significantly increase serious adverse-event risk versus placebo.
In plain wordsIn stroke patients, Cerebrolysin did not significantly increase serious side-effect risk compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Relative risk
1.2
Serious adverse events, Cerebrolysin versus placebo
95% confidence interval for relative risk
0.86 to 1.66
Serious adverse events, Cerebrolysin versus placebo
P value for relative risk comparison
0.29
Serious adverse events, Cerebrolysin versus placebo
Source sentences
Summary
risk of serious adverse events (RR 1.20, 95% CI 0.86-1.66, P=0.29)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 1,649 patients with AIS were pooled from six randomized controlled trials (RCTs).
Report a problemFND-2845852105
06HumanSystematic reviewSafety outcome
In patients with acute ischemic stroke, Cerebrolysin did not significantly change mortality versus placebo.
In plain wordsIn stroke patients, Cerebrolysin did not significantly change death risk compared with placebo.
Peptide
Cerebrolysin
Outcome
No significant changeMortality
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Measurements
Relative risk
0.86
Mortality, Cerebrolysin versus placebo
95% confidence interval for relative risk
0.57 to 1.31
Mortality, Cerebrolysin versus placebo
P value for relative risk comparison
0.49
Mortality, Cerebrolysin versus placebo
Source sentences
Summary
the mortality rate (RR 0.86, 95% CI 0.57-1.31, P=0.49).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 1,649 patients with AIS were pooled from six randomized controlled trials (RCTs).
Report a problemFND-2845852106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.